Cargando…
Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial
BACKGROUND: The effectiveness and safety of Huashibaidu granule (HSBD) in treating mild Corona Virus Disease 2019 (COVID-19) patients infected with SARS-CoV-2 remain to be identified. We aimed to evaluate the effectiveness of HSBD in mild COVID-19 patients. METHODS: A prospective, non-randomized, co...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121152/ https://www.ncbi.nlm.nih.gov/pubmed/37192979 http://dx.doi.org/10.1016/j.imr.2023.100950 |
_version_ | 1785029321850617856 |
---|---|
author | Chen, Bowu Xue, Yan Jing, Hua Wang, Xiaodong Zhu, Peimin Hao, Weiwei Li, Man Gao, Yueqiu |
author_facet | Chen, Bowu Xue, Yan Jing, Hua Wang, Xiaodong Zhu, Peimin Hao, Weiwei Li, Man Gao, Yueqiu |
author_sort | Chen, Bowu |
collection | PubMed |
description | BACKGROUND: The effectiveness and safety of Huashibaidu granule (HSBD) in treating mild Corona Virus Disease 2019 (COVID-19) patients infected with SARS-CoV-2 remain to be identified. We aimed to evaluate the effectiveness of HSBD in mild COVID-19 patients. METHODS: A prospective, non-randomized, controlled study in mild COVID-19 patients was conducted in Shanghai, from April 8 to May 6, 2022. The enrolled patients were diagnosed as mild COVID-19. Finally, 360 patients received HSBD, and 368 patients received TCM placebo (administered orally 20 g twice daily for 7 days). The primary endpoints were the negative conversion rate of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the negative conversion time. Secondary endpoints included the hospitalized days and the improvement in the clinical condition. RESULTS: The negative conversion rate of SARS-CoV-2 at 7 days posttreatment in the HSBD group was higher than that in the control group (95.28% vs. 82.61%, P < 0.001). The median negative conversion time in the HSBD group was markedly decreased by 2 days compared with the control group (3 [3–6] vs. 5 [4–7], P < 0.001). In addition, the median hospitalized day was shortened in the HSBD group by 1 day compared with the control group (6 [4–7] vs. 7 [5–9], P < 0.001). The clinical improvement rate (275/360 [76.39%]) in the HSBD group within 7 days was significantly higher than that (203/368 [55.16%]) in the control group (P < 0.001). The improvement of symptom scores in the HSBD group was higher than that in the control group (2 [1–4] vs. 1 [1–2], P < 0.001). No severe adverse events occurred. CONCLUSIONS: Our study suggested that HSBD effectively increased the negative conversion rate of SARS-CoV-2 and shortened the negative conversion time and hospitalized days in mild COVID-19 patients. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2200058668 |
format | Online Article Text |
id | pubmed-10121152 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-101211522023-04-24 Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial Chen, Bowu Xue, Yan Jing, Hua Wang, Xiaodong Zhu, Peimin Hao, Weiwei Li, Man Gao, Yueqiu Integr Med Res Original Article BACKGROUND: The effectiveness and safety of Huashibaidu granule (HSBD) in treating mild Corona Virus Disease 2019 (COVID-19) patients infected with SARS-CoV-2 remain to be identified. We aimed to evaluate the effectiveness of HSBD in mild COVID-19 patients. METHODS: A prospective, non-randomized, controlled study in mild COVID-19 patients was conducted in Shanghai, from April 8 to May 6, 2022. The enrolled patients were diagnosed as mild COVID-19. Finally, 360 patients received HSBD, and 368 patients received TCM placebo (administered orally 20 g twice daily for 7 days). The primary endpoints were the negative conversion rate of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the negative conversion time. Secondary endpoints included the hospitalized days and the improvement in the clinical condition. RESULTS: The negative conversion rate of SARS-CoV-2 at 7 days posttreatment in the HSBD group was higher than that in the control group (95.28% vs. 82.61%, P < 0.001). The median negative conversion time in the HSBD group was markedly decreased by 2 days compared with the control group (3 [3–6] vs. 5 [4–7], P < 0.001). In addition, the median hospitalized day was shortened in the HSBD group by 1 day compared with the control group (6 [4–7] vs. 7 [5–9], P < 0.001). The clinical improvement rate (275/360 [76.39%]) in the HSBD group within 7 days was significantly higher than that (203/368 [55.16%]) in the control group (P < 0.001). The improvement of symptom scores in the HSBD group was higher than that in the control group (2 [1–4] vs. 1 [1–2], P < 0.001). No severe adverse events occurred. CONCLUSIONS: Our study suggested that HSBD effectively increased the negative conversion rate of SARS-CoV-2 and shortened the negative conversion time and hospitalized days in mild COVID-19 patients. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2200058668 Elsevier 2023-06 2023-04-21 /pmc/articles/PMC10121152/ /pubmed/37192979 http://dx.doi.org/10.1016/j.imr.2023.100950 Text en © 2023 Korea Institute of Oriental Medicine. Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Chen, Bowu Xue, Yan Jing, Hua Wang, Xiaodong Zhu, Peimin Hao, Weiwei Li, Man Gao, Yueqiu Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial |
title | Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial |
title_full | Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial |
title_fullStr | Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial |
title_full_unstemmed | Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial |
title_short | Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial |
title_sort | effectiveness of chinese medicine formula huashibaidu granule on mild covid-19 patients: a prospective, non-randomized, controlled trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121152/ https://www.ncbi.nlm.nih.gov/pubmed/37192979 http://dx.doi.org/10.1016/j.imr.2023.100950 |
work_keys_str_mv | AT chenbowu effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT xueyan effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT jinghua effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT wangxiaodong effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT zhupeimin effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT haoweiwei effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT liman effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial AT gaoyueqiu effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial |